Duloxetine Capsule, Delayed Release
Product Images NDC 68788-7935

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 68788-7935). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Preferred Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Duloxetine Delayed Release Cap Usp 30mg

Duloxetine Delayed Release Cap Usp 30mg
This is a description of a medication named Duloxetine Delayed-Release Cap. It is a USP 30mg capsule that contains Duloxetine. The manufacturer is Ajanta Pharma USA Inc, and the product is a generic alternative for Cymbalta. The document also contains information such as lot number, package size, expiration date, and cautions about the federal law.*
FDA Label Image

Figure1 (Duloxetine Fig1)

FDA Label Image

Figure10 (Duloxetine Fig10)

Figure10 (Duloxetine Fig10)
This is a description of a medication regimen for pain relief involving the drug Duloxetine, which is taken once a day in doses of 60 or 120mg. The document includes a chart indicating improvement in pain levels over time as a percentage.*
FDA Label Image

Figure2 (Duloxetine Fig2)

Figure2 (Duloxetine Fig2)
The text above is a graph showing the proportion of patients with relapse over time from randomization to relapse, for two treatments: Placebo and Duloxetine. The x-axis represents the time from randomization to relapse (in days), while the y-axis shows the proportion of patients with relapse (from 0 to 10%).*
FDA Label Image

Figure3 (Duloxetine Fig3)

Figure3 (Duloxetine Fig3)
This is a table showing the percentage of patients improved for different doses of Duloxetine (60mg BID, 60mg QD, and 20mg QD) in comparison to placebo in terms of pain improvement from baseline.*
FDA Label Image

Figure4 (Duloxetine Fig4)

FDA Label Image

Figure5 (Duloxetine Fig5)

Figure5 (Duloxetine Fig5)
This is a table showing the percentage of patients who improved based on different treatments for pain. The treatments listed are Dulozetine 60mg twice daily, Duloxetine 60mg once daily, and Placebo. The table also shows the percent improvement in pain from baseline.*
FDA Label Image

Figure6 (Duloxetine Fig6)

FDA Label Image

Figure8 (Duloxetine Fig8)

Figure8 (Duloxetine Fig8)
This text describes a medication called Duloxetine, which is taken once daily at a dose of either 60mg or 120mg. The name "Placebo" is mentioned but it is unclear how it relates to the medication. There is a table or graph labeled "Percent Improvement in Pain from Baseline (BOCF)" but no additional information is provided about it. The final line of text appears to be gibberish and may have been affected by the .*
FDA Label Image

Figure9 (Duloxetine Fig9)

Figure9 (Duloxetine Fig9)
This is a report on the effectiveness of Placebo and Duloxetine 60 mg at reducing pain. The report presents a graph of percent improvement in pain from baseline, with different time intervals represented on the x-axis, and percent improvement on the y-axis. The text also includes some numbers and symbols that are not easily interpreted.*
FDA Label Image

Structure (Duloxetine Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.